Tuesday, November 22, 2022
HomeVenture CapitalInvesting in Vicinitas Therapeutics | Andreessen Horowitz

Investing in Vicinitas Therapeutics | Andreessen Horowitz

Vicinitas (noun), Latin
Neighborhood, nearness, proximity, neighborhood

Small molecules, or synthesized chemical compounds, are a few of our most necessary and most acknowledged medication (assume Lipitor). Regardless of their success, small molecules have been restricted by the varieties of therapeutic mechanisms of motion or organic goal courses they will sort out. Over the previous few a long time, biotechnology has crammed this void with new and modern medicines: Massive molecules, or therapeutic proteins, can exchange lacking hormones within the physique like insulin; programmable medicines like CRISPR provide the tantalizing prospect of genetic cures. But, regardless of this increasing therapeutic arsenal, small molecules have remained a mainstay of drugs, making up 75 p.c of all new medicines permitted within the US in 2020. They are often delivered orally, are usually simpler to synthesize/manufacture, and are considerably cheaper than extra complicated medicines like gene therapies. All issues being equal, a small molecule is most well-liked over different therapeutic modalities — if it might probably get the job accomplished.

New instruments have ushered in a sharper, extra exact period of drugs, more and more giving us skills to create small molecules with new superpowers to sort out higher-hanging fruit like beforehand “undruggable” targets. DNA-encoded libraries carry ever-greater range to discover new chemical area. Synthetic intelligence helps generate new goal insights and design higher molecules. Scientists are even growing small molecules with totally new functionalities, similar to PROTACs. PROTACs are bi-functional small molecules that carry collectively two proteins to tag (ubiquitinate) a goal protein for degradation and disposal. We’re in a second golden age for small molecules; scientists are discovering novel methods to construct on and increase on their strengths — they’re instructing good canines new methods.

“That is actually cool!” My companion Becky Pferdehirt had simply shared the hyperlink to a current paper simply posted to bioRxiv on an inner group Slack channel and added a couple of alternative emojis to point out her pleasure. The paper demonstrated the primary ever design and use of a bi-functional small molecule to recruit a protein (OTUB1) that removes ubiquitination tags from proteins to maintain focused proteins from being degraded. These compounds, dubbed DUBTACs, are in essence the mirror picture of PROTACs – as a substitute of degradation, they promote focused protein stabilization. Many cancers and monogenic ailments are brought on by particular proteins which can be abnormally degraded and misplaced from the cell. By stabilizing these proteins, DUBTACs might turn into a completely novel method to deal with illness – and all with a small molecule!

“This needs to be an organization; we’ve received to speak to Dan ASAP,” insisted Becky. Dan Nomura is a professor of chemical biology at UC Berkeley, and a repeat biotech founder; he was considering the identical factor. His lab had developed the DUBTAC platform as a part of a novel academic-industry collaboration with Novartis Institutes for BioMedical Analysis (NIBR). Our companion Judy Savitskaya, who, like Becky, holds a PhD from Berkeley, knew Dan and arranged a gathering. Over a patio dinner that went lengthy into a cold Northern California evening, Dan painted his imaginative and prescient and ambitions for a DUBTAC newco. I then met with Jay Bradner, president of NIBR, in Cambridge. Over beers, chicharrón and too many tacos, Jay additionally expressed his enthusiasm for DUBTACs and need to discover a “inventive experiment” to nurture this innovation exterior of Novartis’ 4 partitions.

It wasn’t lengthy earlier than Becky and I began working in earnest with Dan, Cam Wheeler and our buddies at Deerfield, and the NIBR group to put down the preliminary basis for Vicinitas. Quickly thereafter, biotech government and Celgene alum George Golumbeski and the Droia group joined our company-building effort and we have been in a position to entice seasoned drug-hunter Dan Marquess as chief scientific officer, Joe Budman as VP of biology, and assemble a visionary scientific advisory board. Vicinitas was formally spun-out from the academic-industry collaboration between the Novartis Institutes for BioMedical Analysis and the College of California, Berkeley and is launching with a $65 million Collection A financing to construct the main protein stabilization platform primarily based on its proprietary DUBTAC know-how. a16z is thrilled to co-lead this financing with Deerfield, with participation from Droia, GV, The Mark Basis for Most cancers Analysis and the Berkeley Catalyst Fund.


The views expressed listed here are these of the person AH Capital Administration, L.L.C. (“a16z”) personnel quoted and usually are not the views of a16z or its associates. Sure data contained in right here has been obtained from third-party sources, together with from portfolio corporations of funds managed by a16z. Whereas taken from sources believed to be dependable, a16z has not independently verified such data and makes no representations in regards to the enduring accuracy of the knowledge or its appropriateness for a given state of affairs. As well as, this content material could embrace third-party commercials; a16z has not reviewed such commercials and doesn’t endorse any promoting content material contained therein.

This content material is offered for informational functions solely, and shouldn’t be relied upon as authorized, enterprise, funding, or tax recommendation. You need to seek the advice of your personal advisers as to these issues. References to any securities or digital property are for illustrative functions solely, and don’t represent an funding suggestion or provide to offer funding advisory companies. Moreover, this content material just isn’t directed at nor meant to be used by any traders or potential traders, and should not below any circumstances be relied upon when making a choice to put money into any fund managed by a16z. (An providing to put money into an a16z fund shall be made solely by the non-public placement memorandum, subscription settlement, and different related documentation of any such fund and needs to be learn of their entirety.) Any investments or portfolio corporations talked about, referred to, or described usually are not consultant of all investments in automobiles managed by a16z, and there will be no assurance that the investments shall be worthwhile or that different investments made sooner or later can have comparable traits or outcomes. An inventory of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not offered permission for a16z to reveal publicly in addition to unannounced investments in publicly traded digital property) is obtainable at https://a16z.com/investments/.

Charts and graphs offered inside are for informational functions solely and shouldn’t be relied upon when making any funding choice. Previous efficiency just isn’t indicative of future outcomes. The content material speaks solely as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these supplies are topic to alter with out discover and should differ or be opposite to opinions expressed by others. Please see https://a16z.com/disclosures for extra necessary data.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments